Hoffmann-La Roche

Works in Cardiovascular · Dermatology · ENT · Genetic & rare · GI & liver · Hematology · Immunology · Infectious disease · Metabolic & endocrine · Musculoskeletal · Neurology · Oncology · Ophthalmology · Psychiatry · Renal & urogenital · Respiratory · Women's health

Hoffmann-La Roche is a clinical trial sponsor. It has 200 active clinical trials with 180,342 planned participants, across 17 therapeutic areas. Since 2021 it has completed 330 trials and stopped 93 early.

Trial track record · since 2021

200Active trials180,342 planned participants
330Completed305 with results posted
93Stopped early22% of finished trials

Financials

No SEC filings under this name. The company is private, listed abroad, or files under a parent.

Fundraising

No SEC Form D filings under this name. A private round is only public when the company files one.

Pipeline · 200 active trials

StageTrialStatus

On the market · 0 products

No marketed products under this name.

Questions about Hoffmann-La Roche

See the rest of this profile

A free account shows the trial list, the financials and the fundraising filings. Pro adds a watchlist: one email when FDA acts on a company you name.

Trial counts are as the sponsor reported them to ClinicalTrials.gov, for trials changed since 2021; latest update 2026-11-06.

Products come from FDA's drug application database and, for vaccines, cell and gene therapies and blood products, FDA's Purple Book of licensed biologics; checked 2026-09-23.

Approve Suite is not affiliated with Hoffmann-La Roche.

See something wrong on this page? Write to info@approvesuite.com and we will check it against the source. How corrections work.